The Trump administration's cuts to medical research grants have disrupted awards once backed by former President Joe Biden's "Cancer Moonshot" initiative.
Late last year, South Carolina Medicaid approved GLP-1s to treat obesity, placing it among the few state programs covering the drugs. But access remains limited.